Just as recombinant DNA unlocked a new era of drug-making, siRNA is now unlocking an era where we don’t just supplement biology – we command it. This month’s recommendation is a company that is category defining in its leadership of the siRNA – and a blue-chip biotech stock that should surge ahead as the industry falls back.
Legal monopolies all have similar traits: They have dominant market share, they have enviable pricing power, and given a lack of alternatives for customers, these companies likely have highly predictable and mostly recurring revenue streams. All of that means big profit margins that flow to the bottom line.
Porter writes that there’s no question that America is going to default. But there is something you can do about it: there’s a simple solution that Porter outlined for readers last fall and clarifies again today.
On Tuesdays we turn the spotlight outside of Porter & Co. to bring you exclusive access to the research, the thinking, and the investment ideas of the analysts who Porter follows.
With gold trading above $3,400 per ounce and looking set to clear new record highs above $3,500, we want to add some precious metals exposure into the portfolio. Specifically, we want to own gold royalty companies. We love the royalty model for its capital efficiency. Royalty companies don’t spend a dime digging through miles of
In today’s Daily Journal, Porter writes that there’s a growing likelihood that the entire U.S. financial system will have to be “reset,” because our government cannot afford these debts.
On Thursday, we sent you the first issue of The Trading Club, consisting of a series of trades. You can find that issue here. In total, we sold nine put options on the stocks mentioned in the original issue, and received $4,710.12 in premiums (including a Pepsi limit order we placed on Friday, which got
